PGAM
REGN icon

Princeton Global Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Princeton Global Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$5.26K – 679
2024
Q3 		$5.26K Buy
+5
New +$5.56K ﹤0.01% 544

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Princeton Global Asset Management's REGN Position: Q4 2024 in Review

Princeton Global Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 5 shares — an estimated $5.26K sold.

Princeton Global Asset Management first reported a position in REGN in Q3 2024 and held it in 1 quarter. The position peaked at $5.26K in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Princeton Global Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 5 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $5.26K.
  • Princeton Global Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Princeton Global Asset Management's Regeneron Pharmaceuticals position peaked at $5.26K in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Princeton Global Asset Management's 13F filing for Q4 2024, filed 24 Jan 2025.